Ainos Inc Stock Price, News & Analysis

Ainos (NASDAQ:AIMD) has received IRB approval from Shuang Ho Hospital for its clinical trial of VELDONA® in treating Sjögren's syndrome. The company plans to commence a site initiation visit around April 2025, pending regulatory approvals. The study will recruit 24 patients for a 24- to 48-week treatment period. Previous U.S. clinical trials, including three Phase 3 studies, demonstrated VELDONA® significantly increases unstimulated whole salivary flow. The trial's primary endpoint is to evaluate VELDONA®'s efficacy in improving salivary flow and alleviating dryness symptoms. Patient recruitment will begin in May 2025, with study completion expected by December 2026.

Ainos (NASDAQ: AIMD) has filed complaints with NASDAQ MarketWatch and the SEC regarding suspicious trading activities in its common stock, particularly concerning large-volume sell orders. The healthcare company, which specializes in AI-powered point-of-care testing and interferon therapeutics, suspects potential regulatory violations and has requested thorough investigation to protect stockholder interests. While regulatory bodies won't confirm any investigation details, Ainos maintains its commitment to market transparency and investor protection.

Ainos (NASDAQ:AIMD) reported Q3 2024 financial results with zero revenue compared to $24,489 in Q3 2023. The company reported a net loss of $3.7M, up from $3.0M in Q3 2023. Operating expenses increased to $3.0M from $2.6M, primarily due to higher R&D investments. Cash position strengthened to $5.2M as of September 30, 2024.

Key developments include securing multi-regional patent assets for AI Nose technology, expanding VELDONA® patent portfolio for coronavirus treatments, and progressing clinical trials for Sjögren's syndrome and HIV-related oral warts. The AI Nose platform achieved 79% accuracy in detecting VOCs in semiconductor factories.

Ainos (NASDAQ:AIMD) has secured exclusive licensing rights for 28 multi-regional patent assets from strategic shareholder Taiwan Carbon Nano Technology (TCNT). The patents cover AI Nose gas sensing technology and a breakthrough nitrogen-oxygen separation technology for medical applications. The new separation technology achieves over 99% purity while using one-third of the energy compared to conventional methods, offering significant cost reduction and environmental benefits.

The patent portfolio spans multiple regions including China, Japan, Korea, Taiwan, Germany, the EU, and the US. The agreement grants Ainos exclusive sales rights for the medical-grade nitrogen-oxygen separation technology, positioning the company for expansion in the advanced medical equipment market.

Ainos (NASDAQ:AIMD) showcased VELDONA®'s clinical progress and market potential in a Water Tower Research podcast. VELDONA®, an oral low-dose interferon-α therapeutic, has undergone 68 clinical studies across 16 indications with 6,000 participants, demonstrating strong safety. The company is focusing on two human studies in Taiwan: oral warts in HIV+ patients and Sjogren's syndrome. Previous trials showed over 75% reduction in wart-affected areas. In animal health, Ainos is exploring VELDONA®'s potential for feline chronic gingivostomatitis. Key milestones include completing the FCGS study by March 2025, filing FDA IND in 2025, completing Taiwan human studies in early 2026, and exploring global licensing opportunities.

Ainos, Inc. (NASDAQ:AIMD) has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial on VELDONA®, a low-dose oral interferon formulation for treating oral warts in HIV-positive patients. The trial, involving 40 participants, will evaluate VELDONA®'s efficacy in combination with antiretroviral therapy. VELDONA® has received orphan drug designation from the FDA, highlighting its potential in addressing an unmet medical need.

The next step is obtaining approval from the Taiwan Food and Drug Administration (TFDA). The application was submitted on August 28, 2024. The Site Initiation Visit is expected in November 2024, with patient enrollment lasting one year. The study is anticipated to conclude by July 2026.

Ainos, Inc. (NASDAQ:AIMD) has been featured in a Water Tower Research report highlighting its upcoming VELDONA® clinical study for Sjogren's syndrome, set to begin in December 2024 in Taiwan. The study will enroll 24 patients to assess VELDONA®'s effectiveness in reducing dryness symptoms over 24-48 weeks. Key points include:

1. Taiwan FDA approval expected by November 2024
2. Trial projected to complete by January 2026
3. Primary endpoint: improvement of saliva secretion and dryness symptoms
4. Secondary endpoints: ESSPRI, ESSDAI, VAS, and salivary gland function
5. Sjogren's syndrome affects up to 1% of the global population
6. Previous U.S. Phase 3 data showed significant improvements

This study follows Ainos' capital-efficient strategy of conducting clinical trials in Taiwan, with a prior VELDONA study for oral warts in HIV+ patients planned for November 2024.

Ainos (NASDAQ:AIMD) has announced plans to conduct a Taiwan clinical study for VELDONA in treating Sjögren's syndrome, a rare autoimmune disease. The study, to be conducted at Taipei Medical University-Shuang Ho Hospital, aims to recruit 24 patients who will take three sublingual VELDONA tablets daily for 24-48 weeks. The primary objective is to evaluate VELDONA's efficacy in improving saliva secretion and dryness symptoms.

The company has previously conducted eight clinical trials in the U.S., including three Phase 3 studies that showed positive benefits in increasing unstimulated whole saliva secretion without significant adverse effects. Ainos expects to complete all regulatory approvals for the Taiwan study by November 2024, with patient enrollment lasting approximately six months. The study is projected to conclude in January 2026.

Ainos, Inc. (NASDAQ:AIMD) has announced a new clinical trial for VELDONA®, its low-dose oral interferon-alpha formulation, to treat oral warts in HIV+ patients on antiretroviral therapy. Water Tower Research has issued a report highlighting key aspects of this upcoming trial:

1. The single-site, double-blind study will commence at the National Taiwan University Hospital by November 2024.

2. The trial will enroll 40 subjects, randomized 3:1 to VELDONA® or placebo.

3. The primary endpoint is a 75% reduction in oral wart surface area over 24 weeks.

4. VELDONA® has received Orphan Drug Designation from the FDA for this indication.

5. The study aligns with Ainos' capital-efficient strategy, as clinical studies in Taiwan are less costly than in the U.S.

6. There are currently no approved therapeutics for oral warts, which affect approximately 49,000 HIV+ patients in the U.S.